文献速递免疫规划慢病防控与筛查

重组与减毒带状疱疹疫苗在患有慢性疾病及免疫功能受损高危成人中预防接种的安全性与有效性

Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions.
PubMed 文献 · Vaccine · 2022-11-29

本综述详述多种临床相关免疫功能受损人群中带状疱疹的风险与疾病负担,并汇总重组带状疱疹疫苗(RZV)与减毒带状疱疹疫苗在这些人群中的关键有效性与安全性数据。研究显示免疫功能受损个体可从带状疱疹疫苗接种中获益,但上述认识尚未完全纳入接种指南与临床诊疗。作者认为临床医生应考虑为符合条件的高危人群接种带状疱疹疫苗,以预防带状疱疹及其相关并发症。

要点

  • 与一般人群相比,因免疫衰老或疾病/免疫抑制治疗而免疫功能受损者带状疱疹及其并发症风险升高。
  • 研究显示免疫功能受损个体接种带状疱疹疫苗可产生免疫应答并提供保护。
  • 美国与欧盟已首批批准重组带状疱疹疫苗用于因免疫缺陷或免疫抑制而有带状疱疹风险的≥18岁成人。

核心结论

  • 免疫功能受损个体可从带状疱疹疫苗接种中获益,但这些认识尚未完全纳入接种指南与临床诊疗。
  • 作者认为临床医生应考虑为符合条件的高危人群接种带状疱疹疫苗,以预防带状疱疹及其相关并发症,从而减轻带状疱疹对医疗系统的负担。

研究设计与样本

  • 本综述详述广泛临床相关免疫功能受损人群中带状疱疹的风险与疾病负担。
  • 本综述汇总重组带状疱疹疫苗与减毒带状疱疹疫苗在这些个体中的关键有效性与安全性数据。

主要发现

  • 与一般人群相比,因免疫衰老的老年人以及因疾病或免疫抑制治疗而免疫功能受损的个体带状疱疹及其相关并发症风险升高,这些并发症可致衰弱并危及生命。
  • 研究显示免疫功能受损个体接种带状疱疹疫苗可产生免疫应答并提供针对感染的保护。
  • 美国与欧盟已首批批准重组带状疱疹疫苗用于因免疫缺陷或免疫抑制而有带状疱疹风险的≥18岁成人。
  • 现有系统综述仅关注有限免疫功能受损条件下的带状疱疹风险,且仅审查了重组带状疱疹疫苗的临床数据。

关键数值与推荐

  • 美国与欧盟已首批批准重组带状疱疹疫苗用于因免疫缺陷或免疫抑制而有带状疱疹风险的≥18岁成人。
  • 电子健康记录与关联的个人健康记录可用于识别并联系符合带状疱疹疫苗接种条件的患者,并提供临床决策支持生成的缺失或延迟接种提醒。

临床怎么用

  • 作者认为临床医生应考虑为符合条件的高危人群接种带状疱疹疫苗,以预防带状疱疹及其相关并发症。
  • 电子健康记录与关联的个人健康记录可用于识别并联系符合带状疱疹疫苗接种条件的患者,并提供临床决策支持生成的缺失或延迟接种提醒。

局限性

  • 现有系统综述仅关注有限免疫功能受损条件下的带状疱疹风险,且仅审查了重组带状疱疹疫苗的临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Compared with the general population, older adults with immune senescence and individuals who are immunocompromised (IC) due to disease or immunosuppressive therapy are at increased risk for herpes zoster (HZ) and its associated complications, which can be debilitating and life-threatening. Vaccination can be an effective strategy against HZ and studies have shown that HZ vaccination in IC individuals can elicit immune responses and provide protection from infection. Recently, the first approvals have been granted in the United States and the European Union for the recombinant HZ vaccine (RZV) in adults ≥ 18 years of age at risk of HZ due to immunodeficiency or immunosuppression. Existing systematic reviews have highlighted the risks for HZ in limited immunocompromising conditions and have only examined clinical data for RZV. This review details the risks and burden of HZ in a broad range of clinically relevant IC populations and summarizes key efficacy and safety data for RZV and live HZ vaccine in these individuals. Research has shown IC individuals can benefit from HZ vaccination; however, these insights have yet to be fully incorporated into vaccination guidelines and clinical care. Clinicians should consider HZ vaccination in eligible at-risk populations to protect against HZ and its associated complications and thereby, reduce the burden that HZ poses on the healthcare system. Electronic health records and linked personal health records could be used to identify and contact patients eligible for HZ vaccination and provide clinical decision support-generated alerts for missing or delayed vaccinations. This review will help clinicians identify eligible IC individuals who may benefit from HZ vaccination. A video abstract linked to this article is available on Figshare https://doi.org/10.6084/m9.figshare.21517605.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sullivan KM, Farraye FA, Winthrop KL, et al. Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions. Vaccine. 2022. PMID: 36460534. doi:10.1016/j.vaccine.2022.10.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。